Further analyses revealed that therapeutic benefit of combined gemcitabine/EGFR inhibition associated with KRAS wild‐type tumour status 179, 180 or development of skin rash in patients, which represents another measure of EGFR inhibitor activity 181. This evidence concerns the gene KRAS and neoplasm.